Geron Corporation Культура компании

Dr. John A. Scarlett, also known as Chip, M.D., has been the Chief Executive Officer of Geron Corporation since September 2011 and its President since January 5, 2012. Dr. Scarlett served as Chief Executive Officer and President of Onyx Therapeutics, Inc. since February 2009. He Co-Founded Ipsen Biopharmaceuticals, Inc. (Formerly Tercica Inc) in 2002 and served as its Chief Executive Officer from February 2002 to October 2008. Dr. Scarlett has been Chief Executive Officer and President of Proteolix, Inc. from February 2009 to November 2009. Dr. Scarlett has nearly 30 years of experience in drug development and commercialization. He served as President of Ipsen Biopharmaceuticals, Inc., from February 2002 to February 27, 2008. From March 1993 to May 2001, Dr. Scarlett served as President and Chief Executive Officer of Sensus Drug Development Corporation. Prior to Tercica, Dr. Scarlett founded Sensus Drug Development Corporation. He Co-founded Covance Biotechnology Services, Inc., in 1995. From 1991 to 1993, he headed the North American Clinical Development Center and served as Senior Vice President of Medical and Scientific Affairs at Novo Nordisk A/S. From 1985 to 1990, Dr. Scarlett served as Vice President of Clinical Affairs and headed the clinical development group of Greenwich Pharmaceuticals, Inc. From 1982 to 1985, he served as Associate Director and subsequently, as Director, of Medical Research and Services of McNeil Pharmaceuticals, a wholly-owned subsidiary of Johnson & Johnson, Inc. He has been an Independent Director of Chiasma, Inc. since February 24, 2015. He serves as Director of Onyx Therapeutics, Inc. He has been a Director of Geron Corporation since September 2011 and CytomX Therapeutics, Inc. since June 13, 2016. Dr. Scarlett served as Director of Ipsen Biopharmaceuticals, Inc. from February 2002 to October 2008. He served as a member of board of directors of Covance Biotechnology Services, Inc. since 2000 and Proteolix, Inc. from February 2009 to November 2009. He received his B.A. degree in chemistry from Earlham College and his M.D. from the University of Chicago, Pritzker School of Medicine. Dr. Scarlett trained in Internal Medicine at the Hospital at the University of Pennsylvania and in Endocrinology and Metabolism at the University of Colorado.

Mrs. Melissa A. Kelly Behrs has been an Executive Vice President of Business Development and Portfolio & Alliance Management at Geron Corporation since July 2014. Mrs. Behrs served as an Executive Vice President of Portfolio and Alliance Management at Geron Corporation since February 11, 2014. Mrs. Behrs served as Senior Vice President of Portfolio & Alliance Management at Geron Corporation since September 2012 and served as its Senior Vice President of Strategic Portfolio Management and Product Development & Manufacturing since May 2011. Mrs. Behrs served as Senior Vice President of Strategic Portfolio Management at Geron Corporation since May 2011. Mrs. Behrs served as Senior Vice President of Therapeutic Development Oncology of Geron Corporation, from January 2007 to May 2011. Mrs. Behrs served as Geron Corporation's Vice President of Oncology since January 2003, Vice President of Corporate Development since April 2002 until January 2003 and General Manager of Research and Development Technologies from April 2001 to April 2002. Mrs. Behrs joined Geron Corporation in November 1998 as Director of Corporate Development. From 1990 to 1998, she worked at Genetics Institute, Inc., serving initially as Assistant Treasurer and then as Associate Director of Preclinical Operations where she was responsible for all business development, regulatory and project management activities for the Preclinical Development function. From 1985 to 1990, Mrs. Behrs held financial management positions at several companies in the high technology industry. She graduated summa cum laude with a B.S. in Accounting from Boston College and received an M.B.A. in finance with high distinction from Babson College.

Dr. Andrew J. Grethlein, Ph.D., has been Executive Vice President of Development and Technical Operations at Geron Corporation since July 2014. Dr. Grethlein served as an Executive Vice President of Technical Operations at Geron Corporation since September 17, 2012 and served as its Acting Head of Research. Dr. Grethlein is a senior executive with over 20 years of biotechnology industry experience. He was the Chief Operating Officer and Executive Vice President at Inspiration Biopharmaceuticals, Inc. from joining in January 2010 to 2012. Prior to joining Inspiration, he was Senior Vice President of Biotechnology & Portfolio Management Team Leader, Hematology, at Ipsen SA from 2008 to 2010. At Ipsen, he held responsibility for planning and execution of worldwide strategy for product and portfolio development in the hematology therapeutic area. Before joining Ipsen, Dr. Grethlein was Senior Vice President, Pharmaceutical Operations at Ipsen Biopharmaceuticals, Inc. from 2003 to 2008, where he was a corporate officer and member of the senior executive team which governed corporate strategy, business/organization planning and company operations and where he held line responsibility for CMC functions and commercial/general management responsibility for the Canadian & Middle East markets. He served as Vice President - Manufacturing at Ipsen Biopharmaceuticals, Inc. from April 2003 to August 2005. Prior to joining Ipsen Biopharmaceuticals, Inc. in 2003, Dr. Grethlein served at Elan Corporation, as Senior Director, South San Francisco Pharmaceutical Operations, with responsibility as site-head for commercial manufacturing operations. From 1995 to 1997, he served as Manager, Biologics Development and Manufacturing for Athena Neurosciences, Inc. Prior to this, he served in various engineering positions for Michigan Biotechnology Institute, a non-profit technology research and business development corporation. Dr. Grethlein received his A.A. degree in liberal arts from Simon's Rock Early College, his B.S. degree in biology from Bates College and his M.S. and Ph.D. in chemical engineering from Michigan State University.

Ms. Olivia Kyusuk Bloom has been the Chief Financial Officer of Geron Corporation since December 07, 2012, Executive Vice President of Finance since February 11, 2014 and its Treasurer since February 2011. Ms. Bloom served as Senior Vice President of Finance of Geron Corporation from December 2012 to February 11, 2014 and also served as its Assistant Secretary. Ms. Bloom served as Controller of Geron Corporation, from 1996 to from 2011. In her role as Controller, she managed Geron Corporation's accounting operations, including internal and external financial reporting, development of internal controls and policies and analyzing and implementing new accounting standards. She has been an employee of Geron Corporation since 1994 and served as its Vice President of Finance from January 2007 to December 2012 and as Chief Accounting Officer from September 2010 to December 2012. Prior to joining Geron Corporation, Ms. Bloom started her career in public accounting at KPMG Peat Marwick andbecame a Certified Public Accountant in 1994. Ms. Bloom graduated Phi Beta Kappa with a B.S. in Business Administration from the University of California at Berkeley.

Mr. Stephen N. Rosenfield, J.D., serves as Executive Vice President at Geron Corporation since February 2012. Mr. Rosenfield has been a General Counsel at Geron Corporation since January 05, 2012 and has also been its Corporate Secretary since October 2011. He serves as Executive Vice President at Geron Corporation since February 2012. He served as an Executive Vice President of Legal Affairs & Human Resources at Geron Corporation since February 11, 2014. Mr. Rosenfield served as General Counsel and Secretary at Ipsen Biopharmaceuticals, Inc. since July 2004 and its Executive Vice President of Legal Affairs since March 2006. Mr. Rosenfield is responsible for overseeing Ipsen Biopharmaceuticals, Inc.'s legal affairs, as well as participating with the senior management team in the strategic development and operations of Ipsen Biopharmaceuticals, Inc. His responsibilities included Ipsen Biopharmaceuticals, Inc.'s financing documents, licensing and commercial agreements, public disclosures, human resources policies and procedures, corporate-wide compliance program, sales and marketing policies, patent strategy, corporate governance, as well as advising the board of directors and board committees. He serves as the General Counsel and Secretary of Topica Pharmaceuticals Inc. Mr. Rosenfield has more than 19 years of legal expertise, including 8 years of pharmaceutical and biotechnology industry experience. He served as Senior Vice President of Legal Affairs of Ipsen Biopharmaceuticals, Inc. from July 2004 to March 2006 and as its Executive Vice President of Legal Affairs since March 2006, Secretary and General Counsel since July 2004. He served as an Executive Vice President of Legal Affairs, General Counsel and Secretary of InterMune Inc. since March 2003. From March 2000 to March 2003, he served as an Executive Vice President of Legal Affairs, Senior Vice President of Legal Affairs, General Counsel and Secretary of InterMune Inc. Prior to working at InterMune from February 1996 to February 2000, Mr. Rosenfield served as an Attorney at Cooley Godward LLP, where he was outside counsel for biotechnology and technology clients, handling public and private financings, public disclosures and corporate governance and advising boards and board committees. From September 1992 to January 1996, he was an Associate at Coblentz Cahen McCabe & Breyer LLP. Mr. Rosenfield's earlier legal counsel experience was in litigation at Coblentz, Patch, Duffy and Bass from 1992 to 1996. Mr. Rosenfield holds Juris Doctor degree from Northeastern University School of Law and a Bachelors of Science degree from Hofstra University.

Andrew Good serves as the Executive Director Finance & Controller of Geron Corporation. Andrew currently resides in the San Francisco Bay Area.

Melissa Behrs serves as the Executive Vice President, Business Development and Portfolio & Alliance Management of Geron Corporation. Melissa currently resides in the San Francisco Bay Area.

Jane Lebkowski serves as the Sr VP Regnerative Medicine of Geron Corporation. Jane currently resides in the San Francisco Bay Area.